• 1
    World Health Organization. Cancer Pain Relief, 2nd edn. Geneva: WHO, 1996.
  • 2
    Quigley C. The role of opioids in cancer pain. BMJ 2005; 331: 8259.
  • 3
    Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 37280.
  • 4
    The Pain Society. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain. A Consensus Statement Prepared on Behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. (accessed 23 April 2007).
  • 5
    Klepstad P, Kaasa S, Cherny N, Hanks G, De Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005; 19: 47784.
  • 6
    Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287333.
  • 7
    IMS Health National Prescription Audit, 2006.
  • 8
    IMS Health MIDAS database, 2005.
  • 9
    Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002; 24: 7190.
  • 10
    Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007; 16: 18194.
  • 11
    Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006; 24: 10512.
  • 12
    Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7: R104651.
  • 13
    Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S8S.
  • 14
    Gutstein HB, Akil H. Opioid Analgesics. New York, NY: McGraw Hill, 2001 (The Pharmacological Basis of Therapeutics).
  • 15
    Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990; 5: 3627.
  • 16
    Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 194353.
  • 17
    Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 64971.
  • 18
    Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 316.
  • 19
    Sanger GJ, Tuladhar BR. The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 3845.
  • 20
    De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 38394.
  • 21
    Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004; 361: 1925.
  • 22
    Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 1987; 243: 492500.
  • 23
    De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 10315.
  • 24
    Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 (Suppl. 2): 1728.
  • 25
    McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004; 11: 39.
  • 26
    Basson M. Constipation. (accessed March 2007).
  • 27
    Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 11548.
  • 28
    Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer patients’ health-related quality of life after the start of morphine therapy. J Pain Symptom Manage 2000; 20: 1926.
  • 29
    Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. J Pain 2001; 93: 24757.
  • 30
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 31
    Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005; 21: 155568.
  • 32
    Fallon M. Constipation in cancer patients: prevalence, pathogenesis and cost-related issues. Eur J Pain 1999; 3: 37.
  • 33
    Leslie J, Bell T, Annunziata K, Freedman D. Opioid-induced constipation compromises pain management and impacts patients quality of life. Anesthesiology 2006; 105: A1490.
  • 34
    McNicol E, Horowicz-Mehler N, Fisk RA et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4: 23156.
  • 35
    Bell T, Milanova T, Grove G et al. OBD symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: results of a US patient survey (PROBE survey). Poster presented at The 25th Annual Scientific Meeting of the American Pain Society. San Antonia, TX, USA.
  • 36
    Bell T, Milanova T, Grove G, Williamson R, Bolge S. Prevalence, severity and impact of opioid-induced GI side effects on the EU: results of a patient survey. Eur J Pain 2006; 10 (Suppl. 1): S173 (Abstract 663)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13–6 September, 2006, Istanbul, Turkey.
  • 37
    Annunziata K, Bell T. Impact of opioid-induced constipation on patients and healthcare resource use. Eur J Pain 2006; 10 (Suppl. 1): S172 (Abstract 659)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13–6 September, 2006, Istanbul, Turkey.
  • 38
    Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001; 5: 23740.
  • 39
    Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006; 10: 20917.
  • 40
    Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 54051.
  • 41
    Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 58793.
  • 42
    Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 254254.
  • 43
    Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; CD004847.
  • 44
    Weschules DJ, Bain KT, Reifsnyder J et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med 2006; 7: 3209.
  • 45
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74: 134754.
  • 46
    Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005; 27: 4325.
  • 47
    Überall M, Müller-Schwege G. Opioid-induced constipation – a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain 2006; 10 (Suppl. 1): S172 (Abstract 656)/Poster presented at the 5th Congress of the European Federation of IASP Chapters (EFIC); 13–6 September, 2006, Istanbul, Turkey.